小蓝视频色情网页版

We鈥檝e all read the headlines–a significant obstacle in keeping the coronavirus from spreading has been the shortage of available tests.

Subscribe to the 小蓝视频色情网页版 Daily

In fact, numerous media outlets just yesterday that New York could soon 鈥渃ompletely run out鈥� of swabs specifically needed for coronavirus testing.

One startup is out to help keep that from happening.

Over the last two weeks, San Francisco-based has quickly shifted its resources from being a 3D printer manufacturer to becoming a medical device manufacturer, and has started production to address the massive shortage of COVID-19 test kits.

, co-founder and CEO of Origin, told 小蓝视频色情网页版 News this afternoon that his company successfully completed a clinical trial of its 3D-printed swab testing kits on April 12.

鈥淲e鈥檙e now using everything we鈥檇 built previously to make these devices,鈥� he said.

A single 鈥淥rigin One鈥� printer can print up to 1,500 swabs in a single print in under eight hours, according to the company. Plus, the startup claims its test swabs are a more reliable and scalable solution than traditional swab manufacturing.

鈥淐omplex, detailed geometries can easily be produced on Origin One and do not require any molds,鈥� the company said in a statement. 鈥淭he test swabs can be produced when needed, anywhere, with only a single material for the supply chain.鈥�

Before and after

Prior to the COVID-19 pandemic, Origin says it had pioneered the concept of Open Additive Manufacturing, or a new way to build based on open materials, extensible software and modular hardware.

Origin One, the company鈥檚 manufacturing-grade 3D printer, uses programmable photopolymerization to precisely control light, heat and force, among other variables, to produce parts. The company worked with a network of partners to develop commercial-grade materials for its system, resulting in what it describes as 鈥渟ome of the toughest and most resilient materials in additive manufacturing.鈥�

But now, manufacturing of that printer is on hold.

鈥淲e鈥檙e not going to leave our customers out to dry,鈥� Prucha told 小蓝视频色情网页版 News. 鈥淲e鈥檒l continue to support them. But as a startup, it鈥檚 hard to have some people work on this new initiative and still work on the regular business. So we鈥檝e decided to focus only on this business as long as it鈥檚 needed.鈥�

Origin was founded in 2015 and is led by alumni from Google and Apple (Prucha was a software engineer there). Investors include , DCM, , , and Joe Montana. The company has raised over its lifetime.

Clinical trial success

Origin has been collaborating with (BIDMC), an academic medical center affiliated with Harvard Medical School, to find a better solution for manufacturing COVID-19 test swabs.

Test swabs are difficult to manufacture and require design features and qualities that include a mix of stiffness and flexibility, biocompatibility, autoclavability, and specimen capture and carrying efficacy, according to Prucha. Traditional test swab production is currently limited to only a couple of factories in the world, he added.

As of April 12, Origin鈥檚 new 3D-printed swab passed an initial clinical evaluation for human factors, materials testing and PCR (polymerase chain reaction) compatibility.

鈥淭he nation鈥檚 need for rapid and widespread testing for COVID-19 has been hampered by a widespread shortage of the swabs needed for testing,鈥� said Ramy Arnaout, MD, 鈥嬧�婦Phil, associate director of the Clinical Microbiology Laboratories at BIDMC, who has led a multidisciplinary effort to resolve the shortage and is overseeing the clinical evaluations of 3D-printed swabs at BIDMC.

鈥淚nnovations in 3D printing hold real promise for our collective efforts to diagnose and treat COVID-19, as well as to flatten the transmission curve,鈥� he said.

Origin鈥檚 test swabs are considered an FDA Class 1 Exempt Device. In addition to BIDMC鈥檚 clinical testing, Origin鈥檚 swabs have gone through 鈥渞igorous testing鈥� with the U.S. Army, Origin material partners, universities including UCLA, and independent medical labs, according to Prucha.

鈥淲hile successful clinical trials are not required to sell this kind of device, it鈥檚 a very strong proof point,鈥� he told 小蓝视频色情网页版 News. 鈥淲e鈥檝e now produced thousands of these devices and are ramping up to produce millions of them in coming weeks as we get more printers online.鈥�

Currently, the company has over 50 printers working on producing swabs.

Looking ahead

Origin designed the swabs using the to rapidly iterate many different versions for BIDMC to evaluate, allowing them to hone in on the best design elements for clinical efficacy and patient comfort. Origin worked closely with its Open Material Network to identify the proper medical grade material and to quickly refine optimal processing conditions.

Origin is also part of a new industry consortium called , which is bringing together the efforts of the 3D printing industry with academia and medical enterprises to supply millions of 3D printed COVID-19 test swabs.

鈥淲e鈥檙e not just scaling up, we鈥檙e printing them as quickly as we can while having put a process in place to ensure reliability and consistency,鈥� Prucha said.

The company has a partnership in the works to distribute its swabs to the top 50 to 100 health care systems in the world, he told 小蓝视频色情网页版 News. For now, health care providers can request information and swabs from Origin鈥檚 website.

鈥淭he demand has been overwhelming, in the millions without us even publishing the results of our trial,鈥� Prucha said 鈥淪pecifically, we鈥檝e got demand for more than half a million swabs immediately from a small number of health care providers.鈥�

Ultimately, he expects demand to be 鈥渋n the tens of millions.鈥�

鈥淲e鈥檙e going to have to work hard to meet that demand,鈥� Prucha said.

Illustration: